Eric Lawitz, MD, explains how pharmacists can raise liver risk with patients with obesity and why a FIB-4 score from routine blood work is a good first step.
|Videos|July 19, 2017
How Are Pharmacy Jobs Changing?
In this clip, Ron Jordan, RPh, FAPhA, Dean of Chapman University School of Pharmacy, gives his take on the future job outlook for pharmacists and how jobs in pharmacy are changing.
Advertisement
In this clip, Ron Jordan, RPh, FAPhA, Dean of Chapman University School of Pharmacy, gives his take on the future job outlook for pharmacists and how jobs in pharmacy are changing.
Advertisement
Related to this article
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1C by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Emergency and ICU pharmacists would be most likely to see pneumonic plague. An expert reviews first-line agents, alternatives, and postexposure prophylaxis.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Rising Gallbladder Complications With GLP-1 Receptor Agonists Call for Closer Pharmacist Monitoring
2
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
3
Pneumonic Plague: What Pharmacists Need to Know About Treatment
4
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
5